Myriad Genetics Inc (NASDAQ: MYGN) stock enjoyed a major increase of 21.1% on 5/8/24. The shares closed at $23.95. Moreover, exceptionally high trading volume at 376% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months and has risen 22.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, MYGN is expected to continue to be a modest Value Builder.
Myriad Genetics has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Myriad Genetics has a very low Appreciation Score of 13 but a good Power Rating of 73, with the Negative Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment